KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2025 value amounting to $561.0 million.

  • Teva Pharmaceutical Industries' Accumulated Expenses fell 9.37% to $561.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $561.0 million, marking a year-over-year decrease of 9.37%. This contributed to the annual value of $624.0 million for FY2024, which is 2.13% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Accumulated Expenses of $561.0 million as of Q3 2025, which was up 16.63% from $481.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Accumulated Expenses ranged from a high of $624.0 million in Q4 2024 and a low of $432.0 million during Q1 2023.
  • For the 3-year period, Teva Pharmaceutical Industries' Accumulated Expenses averaged around $524.3 million, with its median value being $492.0 million (2024).
  • In the last 5 years, Teva Pharmaceutical Industries' Accumulated Expenses fell by 17.81% in 2021 and then rose by 16.79% in 2024.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Accumulated Expenses stood at $563.0 million in 2021, then climbed by 0.53% to $566.0 million in 2022, then climbed by 7.95% to $611.0 million in 2023, then grew by 2.13% to $624.0 million in 2024, then fell by 9.37% to $561.0 million in 2025.
  • Its last three reported values are $561.0 million in Q3 2025, $481.0 million for Q2 2025, and $474.0 million during Q1 2025.